Department of Public Health Sciences, Division of Occupational and Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
Inhal Toxicol. 2012 Aug;24(10):645-51. doi: 10.3109/08958378.2012.708065.
Particulate air pollution, for example, from ultrafine (UF) particles, has negative health effects. However, there is still limited knowledge regarding the fate of inhaled particles in the human body.
To describe the normal lung deposition and 1 week particle retention of indium-111 labeled UF carbon particles in healthy subjects. Additionally, the possibility to extend the follow-up period to 4 weeks was also investigated for one of the subjects.
The cumulative pulmonary particle clearance 1 week post-administration, corrected for activity leaching and mucocilliary transport of activity deposited in the central airways, was 4.3 ± 8.5% (average ± standard deviation at group level), with marginal translocation of particles from lungs to blood, 0.3%. There was no observable elimination of particles from the body via urine. Seven days after exposure, the cumulated activity leaching was 3% (group level), which indicates a stable bonding between the particles and Indium-111. The volunteer followed for a total of 4 weeks, showed a cumulative decrease of activity retention in the lungs of 10.5%. After correction for activity leaching and clearance from central airway deposition, the estimated particle clearance was about 2%.
No evidence for particle translocation from the lungs could be proven 7 days after exposure. It is possible to follow-up Indium-111 labeled UF carbon particles at least 1 month post-administration without increasing the administered activity.
例如，来自超细（UF）颗粒的颗粒物对健康有负面影响。然而，对于吸入人体的颗粒的命运，人们的了解仍然有限。
描述健康受试者吸入的铟-111 标记 UF 碳颗粒在肺部的正常沉积和第 1 周的颗粒保留情况。此外，还研究了其中一位受试者将随访时间延长至 4 周的可能性。
校正了活性浸出和沉积在中央气道的活性的黏液纤毛转运，在给药后第 1 周的累积肺颗粒清除率为 4.3±8.5%（组水平的平均值±标准差），颗粒有少量从肺部转移到血液中，占 0.3%。未观察到颗粒通过尿液从体内排出。暴露 7 天后，累积的活性浸出率为 3%（组水平），这表明颗粒与铟-111 之间存在稳定的结合。该志愿者总共随访了 4 周，肺部的累积活性保留量下降了 10.5%。校正活性浸出和中央气道沉积清除后，估计的颗粒清除率约为 2%。
在暴露后 7 天，没有证据表明颗粒从肺部转移。在给药后至少 1 个月内，可以使用铟-111 标记 UF 碳颗粒进行随访，而无需增加给予的活性。
